Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its target price increased by TD Cowen from $96.00 to $105.00 in a report released on Friday morning,Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock.
HALO has been the subject of a number of other research reports. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price target for the company in a report on Friday. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday. Finally, HC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $91.20.
Get Our Latest Report on Halozyme Therapeutics
Halozyme Therapeutics Price Performance
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 232.11% and a net margin of 24.86%.The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the business earned $1.54 earnings per share. The company’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts expect that Halozyme Therapeutics will post 7.54 EPS for the current year.
Insider Activity at Halozyme Therapeutics
In other news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,477 shares of company stock valued at $5,102,643 over the last quarter. 2.50% of the stock is owned by insiders.
Institutional Trading of Halozyme Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. MidFirst Bank acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $27,000. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Halozyme Therapeutics during the second quarter worth $28,000. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Finally, Harbour Investments Inc. lifted its stake in Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.
Key Stories Impacting Halozyme Therapeutics
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
- Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
- Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
- Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
- Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Read More
- Five stocks we like better than Halozyme Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
